Literature DB >> 31030951

Application of multifold characteristic ion filtering combined with statistical analysis for comprehensive profiling of chemical constituents in anti-renal interstitial fibrosis I decoction by ultra-high performance liquid chromatography coupled with hybrid quadrupole-orbitrap high resolution mass spectrometry.

Yueping Jiang1, Rui Liu1, Jingjing Chen1, Manhua Liu1, Min Liu1, Bin Liu1, Lunzhao Yi2, Shao Liu3.   

Abstract

A Chinese herbal formula of Anti-Renal Interstitial Fibrosis I Decoction (ARIF I) is composed of Eucommia ulmoides Oliv., Scutellaria baicalensis Georgi, and Rheum. officinale Baill., and it has been used for the treatment of chronic kidney disease for many years. However, the comprehensive chemical analysis of the formulated ARIF I has yet to be clarified. In this study, an ultra-high performance liquid chromatography coupled with hybrid quadrupole-orbitrap high resolution mass spectrometry (UHPLC/Q-orbitrap HRMS) method executed in full scan/data-dependent MS2 (full MS/dd-MS2) mode has been established in negative ion mode to analyze the major chemical constituents in ARIF I as well as in its three constituent herbs. To rapidly and efficient identify these compounds, we employed a combination of statistical analysis of the MS2 data and fragmentation pathway method to screen for elementary characteristic ions and sub-characteristic ions. Then, we applied multifold characteristic ion filtering to comprehensively profile ARIF I extract chemical constituents with diverse structures. A total of 360 compounds, including anthraquinones, sennosides, galloyl glucoside derivatives, catechin and its derivatives, flavonoids, iridoids, phenylpropanoids, lignan, organic acid, and other compounds were rapidly identified or tentatively characterized by multifold characteristic ion filtering based on their accurate mass spectra (within 5 ppm error) and structure types or by comparison with reference standards. All the ARIF I compounds were also detected in the individual constituent herbs. This study provides a basis for further pharmacokinetic studies of ARIF I and may help in the discovery of new chemical drugs to treat chronic kidney disease. This study also provides a more efficient approach for the screening of appropriate characteristic ions, and a practical strategy for the detection of the types of compounds identified in this study in other herbal medicines.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-Renal interstitial fibrosis I decoction; Multifold characteristic ion filtering; Statistic analysis; Structural characterization; UHPLC/Q-orbitrap HRMS

Mesh:

Substances:

Year:  2019        PMID: 31030951     DOI: 10.1016/j.chroma.2019.04.051

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  4 in total

1.  Rapid characterization of the chemical constituents of Sanhua decoction by UHPLC coupled with Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Yanhui Zhao; Miao Wang; Lin Sun; Xue Jiang; Min Zhao; Chunjie Zhao
Journal:  RSC Adv       Date:  2020-07-10       Impact factor: 3.361

2.  Emodin Retarded Renal Fibrosis Through Regulating HGF and TGFβ-Smad Signaling Pathway.

Authors:  Fan Yang; Lu Deng; JinPeng Li; MuHu Chen; Ying Liu; YingChun Hu; Wu Zhong
Journal:  Drug Des Devel Ther       Date:  2020-09-03       Impact factor: 4.162

3.  Rapid characterization of chemical constituents of Shaoyao Gancao decoction using UHPLC coupled with Fourier transform ion cyclotron resonance mass spectrometry.

Authors:  Lin Sun; Min Zhao; Yanhui Zhao; Xue Jiang; Miao Wang; Yixin Zhang; Chunjie Zhao
Journal:  RSC Adv       Date:  2020-08-11       Impact factor: 4.036

4.  An integrated strategy for the comprehensive profiling of the chemical constituents of Aspongopus chinensis using UPLC-QTOF-MS combined with molecular networking.

Authors:  Fengyu Zhang; Bichen Li; Ying Wen; Yanyang Liu; Rong Liu; Jing Liu; Shao Liu; Yueping Jiang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.